Business
-
Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and… Read more . . .
-
According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of… Read more . . .
-
The Australian Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative is providing over AU $15 million to Atisama Therapeutics (formerly Rage Bio) and Monash University to support continued development of RB042 inhaled… Read more . . .
-
Canadian biotech Zymeworks has agreed to pay $17 per share, a total of approximately $929 million, to acquire Theravance Biopharma, the companies have announced. The deal, which is subject to approval by Theravance shareholders, is… Read more . . .
-
The European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio are among those contributing to a €40 million financing to support development of Leyden Laboratories’ antiviral nasal sprays the company said. Since the beginning of… Read more . . .
-
University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… Read more . . .
-
MannKind Corporation announced that a grant from Breakthrough T1D (formerly JDRF) will be used to support the Phase 2 INHALE-1ST trial of Afrezza in children aged 10 and up with a recent Type 1 diabetes diagnosis, which was initiated earlier… Read more . . .
-
SpliSense announced that it has secured up to $13 million in new funding from the Cystic Fibrosis Foundation to support an ongoing Phase 2 trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic… Read more . . .
-
According to DPI developer Iconovo, the company has now signed a strategic collaboration deal with CDMO Lonza for development of spray dried formulation of inhaled biologics. In January 2025, Iconovo said that Lonza would develop spray dried… Read more . . .
-
Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal